Aadi Bioscience Files 8-K: Agreements, Equity Sales, Officer Changes
Ticker: WHWK · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1422142
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, officer-changes
TL;DR
Aadi Bioscience inked a deal, sold some stock, and swapped out some execs. Big moves happening.
AI Summary
On December 19, 2024, Aadi Bioscience, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and announced changes in its board and officer composition, including the departure of directors and the election of new officers. Additionally, compensatory arrangements for certain officers were detailed, and Regulation FD disclosures were made.
Why It Matters
This filing indicates significant corporate activity, including new agreements and potential equity dilution, alongside changes in leadership which could impact the company's strategic direction.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Aadi Bioscience, Inc. (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Aadi Bioscience, Inc. on December 19, 2024?
The filing states that Aadi Bioscience, Inc. entered into a Material Definitive Agreement on December 19, 2024, but the specific details of this agreement are not provided in this document.
Were there any unregistered sales of equity securities by Aadi Bioscience, Inc. reported in this filing?
Yes, the filing indicates that there were unregistered sales of equity securities by Aadi Bioscience, Inc.
What changes occurred regarding Aadi Bioscience, Inc.'s directors or officers?
The filing reports on the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Were any compensatory arrangements for certain officers disclosed?
Yes, the filing mentions compensatory arrangements of certain officers.
What is the fiscal year end for Aadi Bioscience, Inc.?
Aadi Bioscience, Inc.'s fiscal year ends on December 31.
Filing Stats: 4,582 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2024-12-20 06:05:31
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share AADI The Nasdaq Stock Mar
- $100,000,000 — tock Purchase") for a purchase price of $100,000,000, subject to customary adjustments for P
- $5,000,000 — n limitations, including a cap equal to $5,000,000 for losses relating to any inaccuracy i
- $3,500,000 — d to pay Purchaser a termination fee of $3,500,000. Specifically, this termination fee is
- $6 million — -refundable, partial upfront payment of $6 million and an additional non-refundable, upfro
- $38 million — onal non-refundable, upfront payment of $38 million within ninety (90) days after the effec
- $265 million — ive from Aadi (a) up to an aggregate of $265 million upon the achievement of certain develop
- $540 million — lestones, and (b) up to an aggregate of $540 million upon the achievement of certain commerc
- $2.40 — "Common Stock"), at a purchase price of $2.40 per share, and (ii) 20,076,500 pre-fund
- $2.3999 — nded Warrants"), at a purchase price of $2.3999 per share, for an aggregate purchase pr
- $100 million — are, for an aggregate purchase price of $100 million (collectively, the "PIPE Financing"). T
- $12,910,000 — d committed to purchase an aggregate of $12,910,000 of shares of common stock and/or Pre-Fu
- $1.8 billion — any until its acquisition by Genmab for $1.8 billion in May 2024. Prior to ProfoundBio, Dr.
- $40,000 — y, Dr. Zhao will be entitled to receive $40,000 per year for service as a member of the
- $106,000 — ally accepted accounting principles) of $106,000, which will vest as to one thirty-sixth
Filing Documents
- d891246d8k.htm (8-K) — 68KB
- d891246dex21.htm (EX-2.1) — 598KB
- d891246dex41.htm (EX-4.1) — 68KB
- d891246dex101.htm (EX-10.1) — 67KB
- d891246dex102.htm (EX-10.2) — 308KB
- d891246dex103.htm (EX-10.3) — 89KB
- d891246dex991.htm (EX-99.1) — 31KB
- d891246dex992.htm (EX-99.2) — 31KB
- g891246ex99_2s10g1.jpg (GRAPHIC) — 72KB
- g891246ex99_2s11g1.jpg (GRAPHIC) — 31KB
- g891246ex99_2s12g1.jpg (GRAPHIC) — 84KB
- g891246ex99_2s13g1.jpg (GRAPHIC) — 83KB
- g891246ex99_2s14g1.jpg (GRAPHIC) — 88KB
- g891246ex99_2s15g1.jpg (GRAPHIC) — 90KB
- g891246ex99_2s16g1.jpg (GRAPHIC) — 96KB
- g891246ex99_2s17g1.jpg (GRAPHIC) — 97KB
- g891246ex99_2s18g1.jpg (GRAPHIC) — 101KB
- g891246ex99_2s19g1.jpg (GRAPHIC) — 78KB
- g891246ex99_2s1g1.jpg (GRAPHIC) — 34KB
- g891246ex99_2s20g1.jpg (GRAPHIC) — 102KB
- g891246ex99_2s21g1.jpg (GRAPHIC) — 100KB
- g891246ex99_2s22g1.jpg (GRAPHIC) — 99KB
- g891246ex99_2s23g1.jpg (GRAPHIC) — 73KB
- g891246ex99_2s24g1.jpg (GRAPHIC) — 69KB
- g891246ex99_2s25g1.jpg (GRAPHIC) — 86KB
- g891246ex99_2s26g1.jpg (GRAPHIC) — 92KB
- g891246ex99_2s27g1.jpg (GRAPHIC) — 110KB
- g891246ex99_2s28g1.jpg (GRAPHIC) — 26KB
- g891246ex99_2s2g1.jpg (GRAPHIC) — 280KB
- g891246ex99_2s3g1.jpg (GRAPHIC) — 37KB
- g891246ex99_2s4g1.jpg (GRAPHIC) — 32KB
- g891246ex99_2s5g1.jpg (GRAPHIC) — 80KB
- g891246ex99_2s6g1.jpg (GRAPHIC) — 99KB
- g891246ex99_2s7g1.jpg (GRAPHIC) — 108KB
- g891246ex99_2s8g1.jpg (GRAPHIC) — 95KB
- g891246ex99_2s9g1.jpg (GRAPHIC) — 87KB
- g891246g1220054527842.jpg (GRAPHIC) — 2KB
- g891246g1220054528143.jpg (GRAPHIC) — 2KB
- 0001193125-24-282407.txt ( ) — 5054KB
- aadi-20241219.xsd (EX-101.SCH) — 3KB
- aadi-20241219_lab.xml (EX-101.LAB) — 18KB
- aadi-20241219_pre.xml (EX-101.PRE) — 11KB
- d891246d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This communication contains "forward-looking statements" based upon Aadi's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements about the structure, timing and completion of the proposed transactions, including, but not limited to, the Purchase Agreement, the Stock Purchase, the License Agreement, and the PIPE Financing; the business of Aadi; the proposed PIPE Financing and its terms; the use of proceeds from the proposed transactions; and the intended benefits from Aadi's license agreement with WuX